Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4 Study of Zytiga in Poor-risk mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients Who Was Failed the First-line CAB (Combined Androgen Blockade) Therapy

NCT02405858 is registered in ClinicalTrials.gov with Janssen Pharmaceutical K.K. as lead sponsor.

NCT NCT02405858
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02405858 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4 Study of Zytiga in Poor-risk mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients Who Was Failed the First-line CAB (Combined Androgen Blockade) Therapy
Lead sponsor
Janssen Pharmaceutical K.K.
Phase
Phase 4
Overall status
Completed
Start date
April 10, 2015
Completion date
December 31, 2017
Enrollment
51 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer